FDA Confirms Serious Injuries and Death from Liver Medication Ocaliva
How the liver drug Ocaliva went from treating PBC to accelerating it.
The nearly decade-long run for the controversial liver drug Ocaliva has officially come to an end. Following years of mounting safety concerns and urgent regulatory warnings, Ocaliva (obeticholic acid) was completely removed from the U.S. commercial market on November 14, 2025.
While Intercept Pharmaceuticals characterized the move as a “voluntary withdrawal,” the reality is far more damning. The exit followed an aggressive push by the U.S. Food and Drug Administration (FDA) after clinical data proved that the drug not only failed to save lives but appeared to be shortening them for many patients.
A Failed "Lifeline" for the PBC Community
Primary Biliary Cholangitis (PBC) is a rare, autoimmune condition where the body attacks its own bile ducts, slowly destroying the liver. For the roughly 130,000 Americans living with this disease, news of a new treatment is usually a cause for celebration. When Ocaliva was first approved in 2016, it was marketed as a breakthrough for patients who didn't respond to standard therapies.
However, for a significant number of patients, the "breakthrough" turned into a medical nightmare. Instead of slowing the progression of liver damage, Ocaliva acted as a catalyst for rapid failure. Lawsuit Legal News has been tracking reports of patients who were medically stable for years, only to experience acute liver decompensation, jaundice, and organ failure within weeks or months of starting the drug.
The Cost of Corporate Silence
The final withdrawal in late 2025 confirmed what many legal analysts and medical experts had been shouting for years: Ocaliva’s risks likely outweigh its benefits. FDA records now link the drug to at least 19 deaths and scores of emergency liver transplants.
As we look at the wreckage left behind, a disturbing question remains: How much did the manufacturer know about these fatal risks while they were generating billions in revenue from a vulnerable patient population? Lawsuit Legal News and our team of lawyers are committed to answering that question and holding the responsible parties accountable for what looks increasingly like a massive failure in corporate transparency.
The "Accelerated Approval" Scandal – Profits Before Proof
The path that led to Ocaliva’s market removal began with a controversial regulatory shortcut known as "accelerated approval." In 2016, the FDA allowed Intercept Pharmaceuticals to begin selling the drug before they had any evidence that it actually helped patients live longer or avoid the need for liver transplants.
Instead of requiring proof of long-term health benefits, the agency allowed the manufacturer to use a "surrogate endpoint" (a lab result involving alkaline phosphatase levels) as a stand-in for actual clinical success. The deal was simple: Intercept could generate revenue immediately, provided they conducted post-market studies to verify the drug’s effectiveness later.
The Failure of the COBALT Study
It took nearly a decade for the truth about Ocaliva’s efficacy to surface. The primary study, known as Study 747-302 or the COBALT study, was meant to prove to the FDA that the medication was safe. Again, this was done after Ocaliva was already being PRESCRIBED TO PATIENTS. Well, spoiler alert, the study ended up providing the exact opposite of what the manufacturer intended.
Lawsuit Legal News has analyzed the data from these trials, which revealed a disturbing trend. Rather than protecting the liver, the study showed that:
- Increased Mortality: Patients taking Ocaliva actually had higher rates of liver-related deaths when compared to those taking a placebo.
- Transplant Requirements: A higher percentage of users on the drug required liver transplants or were added to surgical waiting lists.
- No Clinical Benefit: After years of testing, the drug could not prove it significantly improved survival or prevented the progression of PBC symptoms.
The downfall of Ocaliva was cemented by its own trial, Study 747-302. This study was supposed to prove the drug's worth; instead, it became the "smoking gun" for litigation.
The trial data showed that patients taking Ocaliva had a higher incidence of "clinical events"—which is medical shorthand for liver transplant and death—than those taking a placebo. For a drug marketed to save lives, these results were a catastrophic failure.
Intercept Profited Over a Billion Dollars While Patients Suffered
While the clinical trials were failing to show a benefit, Intercept Pharmaceuticals was successfully marketing Ocaliva as a high-priced "orphan drug." Because it treated a rare disease, the company was able to charge premium prices, leading to billions of dollars in revenue while the drug remained on pharmacy shelves.
We find this timeline particularly troubling. It means that for over eight years, PBC patients were essentially acting as unwitting test subjects for a drug that had not yet proven its worth. While the company’s stock price and revenue grew, the patients taking the medication were facing risks of "paradoxical" liver damage that the manufacturer was slow to fully disclose.
A Timeline of the Dangerous Liver Medication Ocaliva
To understand why Lawsuit Legal News is investigating these claims, it is essential to look at the mounting evidence that accumulated over nearly a decade. The history of Ocaliva is a series of "too little, too late" warnings that culminated in the drug's total removal from the market.
- May 27, 2016 – Accelerated Approval: The FDA grants early approval to Ocaliva for PBC patients. The drug is brought to market based on lab results (surrogate endpoints) rather than proof that it actually extends lives.
- February 1, 2018 – The First "Black Box" Warning: Following 19 reported deaths and multiple cases of severe liver injury, the FDA issues its most serious safety alert. The warning highlights that the drug was being incorrectly dosed, leading to fatal liver failure.
- May 26, 2021 – Critical Use Restrictions: The FDA officially restricts Ocaliva’s use, stating it should no longer be prescribed to patients with advanced cirrhosis because it can cause serious harm, including the need for liver transplants.
- November 12, 2024 – Full Approval Denied: After reviewing the long-awaited COBALT study data, the FDA denies full approval for Ocaliva. An advisory committee votes 13-1 that the drug’s benefits do not outweigh its clinical risks.
- December 12, 2024 – New Injury Alerts: The FDA issues a safety communication identifying new cases of serious liver injury even in patients without cirrhosis. The agency flags 20 more instances of transplant or death since 2021.
- September 11, 2025 – Voluntary Withdrawal Announced: Intercept Pharmaceuticals announces it will pull Ocaliva from the U.S. market at the FDA's request.
- November 14, 2025 – Commercial Exit: Ocaliva is officially removed from U.S. pharmacy shelves.
Lawsuit Legal News and our team of lawyers believe that these warnings came far too late for thousands of families. By the time the 2021 and 2024 restrictions were in place, the damage had already been done to many patients who believed they were taking a safe, FDA-approved medication.
Pursuing a claim isn't just about the financial recovery; it is about sending a message to the pharmaceutical industry that "accelerated approval" is not a license to overlook safety signals while collecting billions in revenue.
Why Is the Maker of Ocaliva Being Sued?
The lawsuits being investigated by Lawsuit Legal News are built on several serious allegations regarding the way Ocaliva was tested, marketed, and sold to the public. Our legal team is focusing on the following core theories of liability:
- Failure to Warn: This is perhaps the most significant allegation. We argue that Intercept Pharmaceuticals knew (or should have known) about the increased risk of liver failure and death long before the 2025 withdrawal. We believe the warnings provided to doctors were insufficient and failed to reflect the true severity of the drug’s toxicity.
- Negligent Misrepresentation: Allegations suggest that the manufacturer overstated the benefits of Ocaliva while downplaying the results of clinical trials like the COBALT study. This misled both patients and physicians into believing the drug was a safe "lifeline" for PBC management.
- Strict Product Liability: This focuses on the drug itself being inherently dangerous. Lawsuits allege that Ocaliva had a "design defect" because its chemical makeup posed a higher risk of liver toxicity than was reasonable, especially considering the lack of proven survival benefits.
- Corporate Negligence: We are investigating whether Intercept failed in its duty to perform adequate post-market surveillance. While the company collected billions in revenue, it allegedly failed to act on early signals of liver decompensation and death in patients who were not previously considered "high risk."
Will the Ocaliva Lawsuits become an MDL?
As of early 2026, the number of lawsuits filed against Intercept Pharmaceuticals continues to grow. Because these cases involve a common set of facts—the same drug, the same manufacturer, and a similar pattern of liver injuries—there is a high likelihood that these individual claims will be consolidated into a Multidistrict Litigation (MDL).
An MDL is a federal legal procedure designed to make the process more efficient. Instead of hundreds of different courts hearing the same evidence about Ocaliva's toxicity, all federal cases would be transferred to a single judge for "pretrial proceedings." This includes discovery (the gathering of internal corporate documents) and "bellwether" trials, which are test cases that help both sides determine the potential value of future settlements.
Lawsuit Legal News and our team of lawyers believe that consolidation into an MDL is the most effective way to hold a massive pharmaceutical company accountable. It allows plaintiffs to pool their resources and evidence, creating a much stronger front against a manufacturer that has already spent millions defending a drug that the FDA ultimately found to be unsafe.
Who Qualifies for an Ocaliva Lawsuit?
We are currently reviewing cases for individuals who were prescribed Ocaliva and meet the following specific qualifications:
- Experienced severe liver injury, cirrhosis progression, or liver failure after taking Ocaliva.
- Required hospitalization, transplant evaluation, or intensive treatment as a result of the medication's effects.
- Have medical documentation linking their health deterioration directly to Ocaliva use.
- Wrongful Death: In cases involving the death of a family member, we are representing families who incurred funeral expenses, lost companionship, or suffered other related damages, both tangible and intangible.
Compensation and Damages for Ocaliva Claims
The goal of filing an Ocaliva lawsuit is to hold the manufacturer accountable for the financial and emotional toll their product has taken on families across the country. Lawsuit Legal News and our team of lawyers are pursuing comprehensive damages to ensure victims are made whole.
Compensation in these cases typically falls into two categories:
Economic Damages
- Medical Expenses: This covers the cost of emergency hospitalizations, ongoing liver care, and the massive expenses associated with organ transplants and lifelong anti-rejection medications.
- Lost Wages: Many victims are forced to leave the workforce or reduce their hours because of their declining health or long recovery times after surgery.
- Future Costs: Our legal analysts work with economic experts to calculate the cost of the specialized care a patient will likely require for the remainder of their life.
Non-Economic Damages
- Pain and Suffering: This accounts for the physical agony of liver failure and the grueling nature of the transplant process.
- Emotional Distress: The trauma of facing a life-threatening illness caused by a trusted medication often leads to significant anxiety and loss of enjoyment of life.
- Wrongful Death Benefits: In cases where a family member has passed away, damages can include funeral costs and compensation for the loss of companionship and support.
How to File a Lawsuit Against Ocaliva
If you believe Ocaliva caused your liver health to decline, you do not have to navigate the legal system alone. Lawsuit Legal News and our team of lawyers use a streamlined process to help victims seek the accountability they deserve without added stress.
Here’s what you can expect when you work with Lawsuit Legal News:
- Initial Case Evaluation: Your first step is to contact Lawsuit Legal News for a free, no-obligation consultation. You will speak with a member of our legal team who will listen to your story and gather the basic facts of your Ocaliva use.
- Speaking with an Attorney: If your situation meets the initial criteria, you will speak directly with one of our experienced pharmaceutical attorneys. They will help determine if you qualify for a claim and explain the legal options available to your family.
- We Handle the Heavy Lifting: Once you decide to move forward, we take over the process entirely. Our team will gather your pharmacy records, medical history, and dosing timelines so you can focus on your health and recovery.
- Constant Communication: You will never be left in the dark. Our team will keep you updated on the progress of your case, any settlement negotiations, and major developments in the national litigation against Intercept Pharmaceuticals.
- No Costs Upfront: We work on a contingency fee basis. Lawsuit Legal News only gets paid if we successfully recover money for you.
Lawsuit Legal News Has a History of Fighting for Victims
Lawsuit Legal News and our team of lawyers have a long history of standing up to the world’s largest pharmaceutical companies when they fail to protect consumers. Our reputation is built on advocating for anyone who has been harmed by dangerous medications through aggressive litigation, including the Ozempic Lawsuit, the Suboxone Tooth Decay Lawsuit, and the Depro-Provera Lawsuit.
We have also provided critical support for families in the NEC Baby Formula Lawsuit and in the ongoing Roblox Lawsuit, where children have been exposed to child predators.
By choosing Lawsuit Legal News, you are partnering with a team that has the resources and experience necessary to pursue justice against corporate giants.
Contact Lawsuit Legal News for a Free Ocaliva Case Evaluation
If you or a loved one took Ocaliva and subsequently suffered from liver failure, required a transplant, or experienced a rapid worsening of your PBC, you deserve to know the truth about what happened. Lawsuit Legal News and our team of lawyers are committed to helping families seek justice and financial recovery after being harmed by medications they were told were safe.
Don't let a pharmaceutical company’s failure to warn you of fatal risks go unanswered. We are ready to listen to your story, answer your questions, and determine if you have grounds for a claim.
You can reach our team by calling us at 866-535-9515 or by filling out our simple online contact form.
We provide free, confidential consultations and work on a contingency fee basis, so you never pay us anything unless we successfully recover compensation for you.
Let Lawsuit Legal News stand by your side and help you hold the manufacturers accountable.
Frequently Asked Questions about Ocaliva Litigation
Why did it take so long for the FDA to pull Ocaliva?
Ocaliva was granted accelerated approval in 2016, which allowed it to stay on the market while the manufacturer conducted "confirmatory" trials. These trials (specifically the COBALT study) took several years to complete. It was only after this data definitively showed a higher risk of death and transplant that the FDA had the leverage to request a market withdrawal.
Is there a class action lawsuit for Ocaliva?
At this stage, most Ocaliva claims are being handled as individual lawsuits. However, this is not the type of case that becomes a class action lawsuit. Instead, cases with widely varying damages but caused by the same product are usually consolidated into what is called an MDL (multi-district litigation). Because a client’s liver injuries might range from moderate jaundice to fatal liver failure, these cases usually start as individual lawsuits and might become MDLs, which allows our lawyers to seek compensation that is specific to your medical bills and personal suffering, rather than a "one size fits all" settlement.
What should I do if my doctor still wants me to take Ocaliva?
As of November 2025, the drug has been removed from the U.S. market. You should consult with your hepatologist immediately to discuss alternative PBC treatments. Do not stop any medication without professional medical advice, but you should speak to your doctor about getting a full review of your liver function if you were taking Ocaliva.
How do I start an Ocaliva claim?
The first step is a free case evaluation. You can contact Lawsuit Legal News to discuss your medical history and the timeline of your injuries. We handle these cases on a contingency fee basis, meaning we only get paid if we successfully recover a settlement or verdict for you.